CymaBay Therapeutics Inc. (NASDAQ:CBAY) finished Wednesday with an addition of $0.23 to close at $12.63, an upside of 1.85 percent. An average of 1,112,080 shares of common stock have been traded in the last five days. There was a gain of $0.06 in the past week, and it reached a new high 39 times over the past 12 months. The last 20 days have seen an average of 1,273,730 shares traded, while the 50-day average volume stands at 1,955,054.
CBAY stock has increased by 15.45% in the last month. The company shares reached their 1-month lowest point of $10.72 on 07/10/23. With the stock rallying to its 52-week high on 08/01/23, shares of the company touched a low of $3.15 and a high of $13.25 in 52 weeks. It has reached a new high 29 times so far this year and achieved 101.44% or $6.36 in price. In spite of this, the price is down -4.68% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
CBAY stock investors should be aware that CymaBay Therapeutics Inc. (CBAY) stock had its last reported insider trading activity 23 days ago on Jul 18. In this transaction, the insider spent $248,519. General Counsel, Quinlan Paul T, disposed of 5,000 shares at a price of $11.81 on Jul 14. The insider now owns more than $59,050 worth of shares. Prior to that, General Counsel Quinlan Paul T went on to Sale 5,000 shares at $10.05 each on Jun 30. An amount of $50,250 was transacted.
Valuation Metrics
CymaBay Therapeutics Inc. (CBAY) stock’s beta is 0.37. Other valuation ratios to consider include the price-to-book (PB) ratio at 11.92.
Financial Health
The quick ratio of CymaBay Therapeutics Inc. for the three months ended March 30 was 5.20, and the current ratio was 5.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.91 and a total debt to equity ratio of 0.91 for the quarter ending March 30. Its gross profit as reported stood at $14.91 million compared to revenue of $93.11 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, CymaBay Therapeutics Inc.’s return on assets was -59.10%.
Earnings Surprise
For the three-month period that ended March 30, CymaBay Therapeutics Inc. had $177.22 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$28.78 million in the quarter, while revenues of -$26.63 million were grew 3.51%. The analyst consensus anticipated CymaBay Therapeutics Inc.’s latest quarter earnings to come in at -$0.09 per share, but it turned out to be -$0.29, a -222.20% surprise. For the quarter, EBITDA amounted to -$27.99 million. Shareholders own equity worth $97.51 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at CymaBay Therapeutics Inc. (CBAY) price momentum. RSI 9-day as of the close on 09 August was 63.41%, suggesting the stock is Neutral, with historical volatility in this time frame at 44.94%.
As of today, CBAY’s price is $12.38 +0.48% or $0.06 from its 5-day moving average. CBAY is currently trading +14.40% higher than its 20-day SMA and +38.18% higher than its 100-day SMA. However, the stock’s current price level is +44.34% above the SMA50 and +286.24% above the SMA200.
The stochastic %K and %D were 57.74% and 55.33%, respectively, and the average true range (ATR) was 0.59. With the 14-day stochastic at 69.53% and the average true range at 0.61, the RSI (14) stands at 63.23%. The stock has reached -0.13 on the 9-day MACD Oscillator while the 14-day reading was at 0.17.
Analyst Ratings
William Blair launched coverage on CymaBay Therapeutics Inc. (NASDAQ: CBAY) in its analyst report released on April 05, 2023. The firm assigned the stock an Outperform rating. The consensus rating for CymaBay Therapeutics Inc. (CBAY) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CBAY, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 11 others rate it as a “buy”.
What is CBAY’s price target for the next 12 months?
Analysts predict a range of price targets between $12.00 and $19.00, with a median target of $16.50. Taking a look at these predictions, the average price target given by analysts for CymaBay Therapeutics Inc. (CBAY) stock is $16.30.
